Kissei Pharmaceutical Co., Ltd.
Clinical trials sponsored by Kissei Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company developing drugs for urology, diabetes, and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug MR13A9 shows promise for Dialysis-Related itching
Symptom relief CompletedThis Phase 2 study tested a drug called MR13A9 in 247 Japanese adults on hemodialysis who had severe itching (uremic pruritus). Participants received either MR13A9 or a placebo intravenously. The goal was to see if the drug reduces itch intensity over 8 weeks. Results could lead …
Phase: PHASE2 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New pill could tame fibroid symptoms without surgery
Symptom relief CompletedThis study tested an oral drug called KLH-2109 in 89 premenopausal Japanese women with uterine fibroids who had heavy bleeding and pain. The goal was to see if the drug could reduce bleeding and pain better than a placebo. The trial was completed and may point to a new way to man…
Phase: PHASE3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
New drug aims to stop the agonizing itch of dialysis
Symptom relief CompletedThis completed Phase 3 trial tested a drug called MR13A9 in 178 adults on hemodialysis who suffer from severe itching (uremic pruritus). The study compared MR13A9 to a placebo to see if it reduces itch intensity, measured by a daily 0-10 rating scale. If successful, MR13A9 could …
Phase: PHASE3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 15:55 UTC